Thomas Klimkait

14.6k total citations · 1 hit paper
186 papers, 7.1k citations indexed

About

Thomas Klimkait is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Thomas Klimkait has authored 186 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Infectious Diseases, 129 papers in Virology and 30 papers in Molecular Biology. Recurrent topics in Thomas Klimkait's work include HIV Research and Treatment (129 papers), HIV/AIDS drug development and treatment (115 papers) and HIV/AIDS Research and Interventions (103 papers). Thomas Klimkait is often cited by papers focused on HIV Research and Treatment (129 papers), HIV/AIDS drug development and treatment (115 papers) and HIV/AIDS Research and Interventions (103 papers). Thomas Klimkait collaborates with scholars based in Switzerland, United States and Germany. Thomas Klimkait's co-authors include Klaus Strebel, María Ángeles Martín, Hans H. Hirsch, Michael J. Mihatsch, Wendy A. Knowles, Jürg Steiger, Jakob Passweg, Michael Dickenmann, François Hamy and Huldrych F. Günthard and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Thomas Klimkait

183 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prospective Study of Polyomavirus Type BK Replication and Nephropathy in Renal-Transplant Recipients

2002 928 citations Thomas Klimkait et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Klimkait Switzerland	43	3.7k	3.6k	1.7k	1.4k	1.4k	186	7.1k
Carlo Federico Perno Italy	56	8.0k 2.2×	6.9k 2.0×	2.5k 1.4×	3.5k 2.5×	861 0.6×	558	13.4k
Lieven Stuyver Belgium	45	3.6k 1.0×	2.7k 0.8×	1.2k 0.7×	5.0k 3.5×	256 0.2×	155	9.2k
Andreas Meyerhans Germany	42	2.1k 0.6×	2.9k 0.8×	2.0k 1.2×	1.8k 1.3×	387 0.3×	173	6.9k
Stephen C. De Rosa United States	39	1.0k 0.3×	1.8k 0.5×	2.0k 1.1×	1.4k 1.0×	803 0.6×	101	7.1k
Julia A. Metcalf United States	50	4.0k 1.1×	5.9k 1.6×	1.4k 0.8×	1.9k 1.3×	400 0.3×	103	9.9k
Samuel Broder United States	57	5.8k 1.6×	5.1k 1.4×	3.0k 1.8×	2.8k 2.0×	1.0k 0.7×	121	12.3k
Daria J. Hazuda United States	59	7.0k 1.9×	7.4k 2.1×	5.5k 3.2×	2.2k 1.6×	618 0.4×	189	13.7k
Neil Parkin United States	41	4.6k 1.3×	4.4k 1.2×	1.2k 0.7×	1.0k 0.7×	92 0.1×	132	6.1k
Kent J. Weinhold United States	50	4.2k 1.1×	6.5k 1.8×	2.6k 1.5×	2.4k 1.7×	684 0.5×	170	10.1k
Katherine Luzuriaga United States	44	6.4k 1.8×	2.9k 0.8×	1.1k 0.6×	2.1k 1.5×	1.3k 0.9×	116	10.1k

Countries citing papers authored by Thomas Klimkait

Since Specialization

Citations

This map shows the geographic impact of Thomas Klimkait's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Klimkait with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Klimkait more than expected).

Fields of papers citing papers by Thomas Klimkait

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Klimkait. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Klimkait. The network helps show where Thomas Klimkait may publish in the future.

Co-authorship network of co-authors of Thomas Klimkait

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Klimkait. A scholar is included among the top collaborators of Thomas Klimkait based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Klimkait. Thomas Klimkait is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schön, Jacob, Donata Hoffmann, Nico Joël Halwe, et al.. (2024). High protection and transmission-blocking immunity elicited by single-cycle SARS-CoV-2 vaccine in hamsters. npj Vaccines. 9(1). 206–206. 1 indexed citations

Lang, Christopher, et al.. (2024). Benefits of Repeated SARS-CoV-2 Vaccination and Virus-induced Cross-neutralization Potential in Immunocompromised Transplant Patients and Healthy Individuals. Open Forum Infectious Diseases. 11(10). ofae527–ofae527. 1 indexed citations

Zhang, Yuepeng, et al.. (2023). Rapid cloning-free mutagenesis of new SARS-CoV-2 variants using a novel reverse genetics platform. eLife. 12. 7 indexed citations

Zhang, Yuepeng, et al.. (2023). Rapid cloning-free mutagenesis of new SARS-CoV-2 variants using a novel reverse genetics platform. eLife. 12. 2 indexed citations

Klimkait, Thomas, Phanankosi Moyo, Karam Mounzer, et al.. (2022). HPLC-Based Purification and Isolation of Potent Anti-HIV and Latency Reversing Daphnane Diterpenes from the Medicinal Plant Gnidia sericocephala (Thymelaeaceae). Viruses. 14(7). 1437–1437. 7 indexed citations

Muhairwe, Josephine, Tracy R. Glass, Alain Amstutz, et al.. (2022). Dolutegravir in real life: Self‐reported mental and physical health outcomes after transitioning from efavirenz‐ to dolutegravir‐based antiretroviral therapy in a prospective cohort study in Lesotho. HIV Medicine. 24(2). 153–162. 3 indexed citations

Amstutz, Alain, et al.. (2021). Extensive drug resistance during low-level HIV viraemia while taking NNRTI-based ART supports lowering the viral load threshold for regimen switch in resource-limited settings: a pre-planned analysis from the SESOTHO trial. Journal of Antimicrobial Chemotherapy. 76(5). 1294–1298. 13 indexed citations

Amstutz, Alain, Thabo Ishmael Lejone, Josephine Muhairwe, et al.. (2021). Offering ART refill through community health workers versus clinic-based follow-up after home-based same-day ART initiation in rural Lesotho: The VIBRA cluster-randomized clinical trial. PLoS Medicine. 18(10). e1003839–e1003839. 10 indexed citations

Amstutz, Alain, Thabo Ishmael Lejone, Michael Hobbins, et al.. (2020). Low rates of active hepatitis B and C infections among adults and children living with HIV and taking antiretroviral therapy: A multicenter screening study in Lesotho. Journal of Medical Virology. 92(12). 3857–3861. 2 indexed citations

10.

Amstutz, Alain, Fiona Vanobberghen, Josephine Muhairwe, et al.. (2020). Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho. PLoS Medicine. 17(9). e1003325–e1003325. 19 indexed citations

11.

Glass, Tracy R., Fiona Vanobberghen, Alain Amstutz, et al.. (2019). The viral load monitoring cascade in a resource-limited setting: A prospective multicentre cohort study after introduction of routine viral load monitoring in rural Lesotho. PLoS ONE. 14(8). e0220337–e0220337. 42 indexed citations

12.

Amstutz, Alain, Isaac Ringera, Josephine Muhairwe, et al.. (2019). Engagement in Care, Viral Suppression, Drug Resistance, and Reasons for Nonengagement After Home-Based Same-Day Antiretroviral Therapy Initiation in Lesotho: A Two-Year Follow-up of the CASCADE Trial. Clinical Infectious Diseases. 71(10). 2608–2614. 16 indexed citations

13.

Amstutz, Alain, Fiona Vanobberghen, Josephine Muhairwe, et al.. (2018). SESOTHO trial (“Switch Either near Suppression Or THOusand”) – switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, Southern Africa. BMC Infectious Diseases. 18(1). 76–76. 4 indexed citations

14.

Scherrer, Alexandra, Viktor von Wyl, Wan-Lin Yang, et al.. (2016). Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. Clinical Infectious Diseases. 62(10). 1310–1317. 39 indexed citations

15.

Cerutti, Bernard, Isaac Ringera, Thabo Ishmael Lejone, et al.. (2015). Still Far From 90-90-90. The Pediatric Infectious Disease Journal. 35(1). 78–80. 6 indexed citations

16.

Vetter, Beatrice, Katrien Fransen, Christoph Niederhauser, et al.. (2014). Generation of a Recombinant Gag Virus-Like-Particle Panel for the Evaluation of p24 Antigen Detection by Diagnostic HIV Tests. PLoS ONE. 9(10). e111552–e111552. 12 indexed citations

17.

Klimkait, Thomas, et al.. (2010). Discovering novel plant-derived drug leads for the treatment of HIV through an integrated approach. Analytical and Bioanalytical Chemistry. 414(29-30). 8413–8421.

18.

Yerly, Sabine, Thomas Junier, Angèle Gayet‐Ageron, et al.. (2009). Impact of newly HIV diagnosed individuals on the transmission of drug resistance. Antiviral Therapy. 14(4).

19.

Klimkait, Thomas. (2000). 'Restriction-PCR' - a Superior Replacement for Restriction Endonucleases in DNA Cloning Applications. BMB Reports. 33(2). 162–165. 3 indexed citations

20.

Klimkait, Thomas, K Woods-Cook, Enrica Alteri, et al.. (1992). The Replicative Restriction of Lymphocytotropic Isolates of HIV-1 in Macrophages Is Overcome by TGF-β. AIDS Research and Human Retroviruses. 8(4). 505–511. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact